预约演示
更新于：2025-05-16
Polyethylene glycol 4000
聚乙二醇4000
更新于：2025-05-16
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1979-04-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C2H6O2 |
InChIKeyLYCAIKOWRPUZTN-UHFFFAOYSA-N |
CAS号25322-68-3 |
关联
22
项与 聚乙二醇4000 相关的临床试验NCT06357897
Faculty of Medicine, Chulalongkorn University
This study aims to evaluate the efficacy and palatability of a developed polyethylene glycol-based formula compared with the standard polyethylene glycol (PEG) in the treatment of children with functional constipation for 8 weeks. Besides, we also aim to assess the side effects of a developed PEG-based formula as well as evaluate the change of rectal diameter from baseline at each visit between 2 groups.
开始日期2024-05-01 |
申办/合作机构 |
NCT06349031
Comparison of Efficacy & Tolerability Of Polyethylene Glycol 4000 Versus Polyethylene Glycol 3350+ Electrolytes For Fecal Disimpaction in Pediatric Functional Constipation: A Double-Blind Randomized Controlled Trial
Childhood constipation is a common but serious gastrointestinal disorder prevalent worldwide. In 90-95% of children, it is of functional origin. Thirty to seventy-five percent of children with functional constipation also have fecal impaction. The treatment strategy for functional constipation includes fecal disimpaction and maintenance therapy to ensure regular bowel movements.
Polyethylene glycol (PEG) based laxatives have been recommended as the first-line therapeutic agents. The commonly used formulations are PEG 3350 with a molecular weight between 3200- 3700 g/mol and PEG 4000 with molecular weight of 4000 g/mol. Both are shown to be effective in pediatric constipation management in placebo-controlled trials. PEG 3350 + Electrolyte (E) is more widely used than PEG 4000 for the management of constipation. This might be because of the perception that PEG 3350 + E is safer in terms of preventing electrolyte imbalance. However, because of the inclusion of electrolytes, PEG 3350+ E solution taste saltier than PEG 4000. Many patients struggle to tolerate the unpleasant taste resulting in the high incidence of non-compliance. To date, no pediatric trials have compared PEG 4000 versus PEG 3350+E for management of Fecal disimpaction.
Present study has been planned to evaluate the efficacy & tolerability of PEG 4000 versus PEG 3350+ E for fecal disimpaction in pediatric functional constipation. Patients between age 1-16 years having functional constipation (as per ROME IV criteria) with fecal impaction will be included. Subjects will be randomly assigned to either PEG 4000 or PEG 3350+E at a ratio of 1:1. They will be stratified into 3 different age groups: 1-5 years, 6-11 years, and 12-16 years. They will receive either of the PEG solutions (as per allocation) at a dose of 1.5 gm/kg/day for 6 consecutive days or till the resolution of fecal impaction whichever is earlier. The resolution of fecal impaction is defined as the passage of clear liquid stool and the disappearance of palpable abdominal fecolith.
Primary outcome is defined as the proportion of subjects achieving fecal disimpaction in each arm.
Secondary outcomes are defined as follows:
Total no of Days required to achieve fecal disimpaction in each arm
Cumulative dose of PEG required for fecal disimpaction in each arm
Proportion of subjects (> 5 years age) reporting palatability issues in each arm
Proportion of subjects discontinuing the treatment due to palatability issues in each arm
Polyethylene glycol (PEG) based laxatives have been recommended as the first-line therapeutic agents. The commonly used formulations are PEG 3350 with a molecular weight between 3200- 3700 g/mol and PEG 4000 with molecular weight of 4000 g/mol. Both are shown to be effective in pediatric constipation management in placebo-controlled trials. PEG 3350 + Electrolyte (E) is more widely used than PEG 4000 for the management of constipation. This might be because of the perception that PEG 3350 + E is safer in terms of preventing electrolyte imbalance. However, because of the inclusion of electrolytes, PEG 3350+ E solution taste saltier than PEG 4000. Many patients struggle to tolerate the unpleasant taste resulting in the high incidence of non-compliance. To date, no pediatric trials have compared PEG 4000 versus PEG 3350+E for management of Fecal disimpaction.
Present study has been planned to evaluate the efficacy & tolerability of PEG 4000 versus PEG 3350+ E for fecal disimpaction in pediatric functional constipation. Patients between age 1-16 years having functional constipation (as per ROME IV criteria) with fecal impaction will be included. Subjects will be randomly assigned to either PEG 4000 or PEG 3350+E at a ratio of 1:1. They will be stratified into 3 different age groups: 1-5 years, 6-11 years, and 12-16 years. They will receive either of the PEG solutions (as per allocation) at a dose of 1.5 gm/kg/day for 6 consecutive days or till the resolution of fecal impaction whichever is earlier. The resolution of fecal impaction is defined as the passage of clear liquid stool and the disappearance of palpable abdominal fecolith.
Primary outcome is defined as the proportion of subjects achieving fecal disimpaction in each arm.
Secondary outcomes are defined as follows:
Total no of Days required to achieve fecal disimpaction in each arm
Cumulative dose of PEG required for fecal disimpaction in each arm
Proportion of subjects (> 5 years age) reporting palatability issues in each arm
Proportion of subjects discontinuing the treatment due to palatability issues in each arm
开始日期2024-04-15 |
JPRN-UMIN000046499
A Retrospective Study on the Effectiveness and Safety of Macrogol 4000, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride in Pregnant Women with Chronic Constipation - A Retrospective Study on the Effectiveness and Safety of Macrogol 4000, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride in Pregnant Women with Chronic Constipation
开始日期2021-11-20 |
申办/合作机构- |
100 项与 聚乙二醇4000 相关的临床结果
登录后查看更多信息
100 项与 聚乙二醇4000 相关的转化医学
登录后查看更多信息
100 项与 聚乙二醇4000 相关的专利（医药）
登录后查看更多信息
82,165
项与 聚乙二醇4000 相关的文献（医药）2025-12-01·Nano-Micro Letters
Rewritable Triple-Mode Light-Emitting Display
Article
作者: Jiang, Wei ; Zhao, Kaiying ; Lee, Chang Eun ; Jung, Jong Gun ; Jang, Jihye ; Kim, Gwanho ; Han, Hyowon ; Oh, Jin Woo ; Park, Jong Woong ; Yoo, Jioh ; Lee, Seokyeong ; Park, Cheolmin ; Yoon, Jungwon
Abstract:
Despite great progress in developing mode-selective light emission technologies based on self-emitting materials, few rewritable displays with mode-selective multiple light emissions have been demonstrated. Herein, we present a rewritable triple-mode light-emitting display enabled by stimuli-interactive fluorescence (FL), room-temperature phosphorescence (RTP), and electroluminescence (EL). The display comprises coplanar electrodes separated by a gap, a polymer composite with FL inorganic phosphors (EL/FL layer), and a polymer composite with solvent-responsive RTP additives (RTP layer). Upon 254 nm UV exposure, a dual-mode emission of RTP and FL occurs from the RTP and EL/FL layers, respectively. When a polar liquid, besides water, is applied on the display and an AC field is applied between the coplanar electrodes, EL from the EL/FL layer is triggered, and the display operates in a triple mode. Interestingly, when water is applied to the display, the RTP mode is deactivated, rendering the display to operate in a dual mode of FL and EL. By manipulating the evaporation of the applied polar liquids and water, the mode-selective light emission of FL, RTP, and EL is rewritable in the triple-mode display. Additionally, a high-security full-color information encryption display is demonstrated, wherein the information of digital numbers, letters, and Morse code encoded in one optical mode is only deciphered when properly matched with that encoded in the other two modes. Thus, this article outlines a strategy to fulfill the substantial demand for high-security personalized information based on room-temperature multi-light-emitting displays.
2025-12-01·Nano-Micro Letters
Dynamic Regulation of Hydrogen Bonding Networks and Solvation Structures for Synergistic Solar-Thermal Desalination of Seawater and Catalytic Degradation of Organic Pollutants
Article
作者: Jiao, Fan-Zhen ; Yu, Zhong-Zhen ; Yin, Guang ; Wu, Jing ; Qu, Jin ; Yu, Ming-Yuan
Abstract:
Although solar steam generation strategy is efficient in desalinating seawater, it is still challenging to achieve continuous solar-thermal desalination of seawater and catalytic degradation of organic pollutants. Herein, dynamic regulations of hydrogen bonding networks and solvation structures are realized by designing an asymmetric bilayer membrane consisting of a bacterial cellulose/carbon nanotube/Co2(OH)2CO3 nanorod top layer and a bacterial cellulose/Co2(OH)2CO3 nanorod (BCH) bottom layer. Crucially, the hydrogen bonding networks inside the membrane can be tuned by the rich surface –OH groups of the bacterial cellulose and Co2(OH)2CO3 as well as the ions and radicals in situ generated during the catalysis process. Moreover, both SO42− and HSO5− can regulate the solvation structure of Na+ and be adsorbed more preferentially on the evaporation surface than Cl−, thus hindering the de-solvation of the solvated Na+ and subsequent nucleation/growth of NaCl. Furthermore, the heat generated by the solar-thermal energy conversion can accelerate the reaction kinetics and enhance the catalytic degradation efficiency. This work provides a flow-bed water purification system with an asymmetric solar-thermal and catalytic membrane for synergistic solar thermal desalination of seawater/brine and catalytic degradation of organic pollutants.
2025-10-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
A photostable luminescent iridium(III) complex probe for imaging endogenous mitochondrial sulfur dioxide in living cells
Article
作者: Jia, Mengzhao ; Wang, Wanhe ; Hu, Bingjie ; Wu, Jia ; Wu, Xiaolei ; Chan, Daniel Shiu-Hin ; Wong, Chun-Yuen ; Leung, Chung-Hang ; Yang, Kai
Sulfur dioxide (SO2) is an important signaling gas molecule, but its aberration is highly associated with inflammatory diseases and cancers. Luminescence probes for SO2 have emerged as essential instruments for elucidating its biological roles and facilitating disease diagnosis, owing to their high sensitivity and capabilities for real-time detection. Nevertheless, the majority of current probes lack subcellular selectivity and suffer from limited photostability. In this work, we develop an Ir(III)-based luminescence probe (Ir3) for the rapid, real-time, and accurate detection of SO2 in aqueous solution. This probe exhibits low cytotoxicity and provides exceptional imaging of mitochondrial SO2 in living cells. We anticipate that this probe will serve as a foundational tool for the advancement of effective imaging technologies for SO2, thereby enhancing the clinical and biomedical applications of Ir(III) complex-based detection probes.
10
项与 聚乙二醇4000 相关的新闻（医药）2025-04-30
OSLO, Norway, April 30, 2025 /PRNewswire/ --
In the first quarter of 2025, Navamedic ASA (OSE: NAVA)
, a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, reported revenues of NOK 132.0 million, representing a 9.2 per cent increase from the same period in 2024. EBITDA reached NOK 12.8 million, up from NOK 8.5 million last year. Gross margin improved to 40.7per cent, compared to 38.7per cent in Q1 2024.
The strong performance was primarily driven by the Hospital area, particularly the antibiotics portfolio, supported by two long-term Nordic tenders secured in 2024. The company also experienced double-digit revenue growth in its Prescription Drugs (RX) area, contributing to the overall growth.
"After investing in several strategic growth initiatives last year, we are pleased to see strong results already in the first quarter of 2025. The positive impact of the Nordic tender wins for our antibiotics portfolio has just begun to materialize. In addition, several products, including Mysimba® and Imdur® from our Prescription Drugs (RX) segment, delivered strong performance in the quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic.
"We are also pleased to announce the renewal of our agreement with TopRidge Pharma, securing the exclusive rights to market and sell Imdur® for another eight years. Over the past few years, we have systematically expanded and matured our product portfolio while investing in initiatives to drive future growth. The strong start to 2025 confirms the progress we are making," she added.
Business area update and Q1 key figures
During the first quarter, the
Prescription Drugs (up 11.5 per cent YoY) and
Hospital (up 15.2 per cent YoY) business areas delivered strong growth.
Consumer Health had a steady development in the period (up 0.3 per cent YoY).
As part of the Prescription Drugs area, revenues of
Mysimba® increased by 7.3 per cent YoY. During the quarter, the European Medicines Agency's Human Medicines Committee also announced its review of Mysimba®. It affirmed that the benefits continue to outweigh the risks for weight management in adults with obesity or overweight.
Imdur® and
Nitrolingual® performed well in the quarter and were up 54 per cent and 22 per cent, respectively.
Flexilev®, the company's unique treatment for Parkinson's Disease, delivered sales growth of 13 per cent YoY.
Forlax® had a revenue decrease of 45 per cent due increased competition.
For the
Hospital area, the two tender wins drove sales growth in the
antibiotics portfolio, which is up 32 per cent YoY, whilst the
Medical Nutrition portfolio maintained steady sales.
The company's third business area,
Consumer Health, delivered stable results. Revenues of
Modifast were steady during Q1, whilst
Absolut Torr (up 49 per cent YoY) and
ThermaCare (up 8 per cent YoY) experienced strong growth.
Eroxon® saw a 9 per cent decrease in revenues, which is explained by a stock build-up in Q1 2024.
Operating results (EBIT) for the first quarter of 2025 amounted to NOK 9.1 million, compared to NOK 4.9 million in 2024. Operating costs ended at NOK 40.9 million, compared to NOK 38.3 million last year. Net financial items ended at negative NOK 11 million and profit before tax was negative NOK 1.8 million.
Outlook
Navamedic continues to see strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company.
"We have had a strong start to 2025. We have several key hero products across our three business areas, many of which have the potential to succeed internationally. Part of our work moving forward will be to identify growth opportunities for these products to support future growth," Andreassen concluded.
Presentation
Navamedic will present the results for the first quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link:
Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: [email protected]
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: [email protected]
About Navamedic
Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway.
For more information, please visit Navamedic.com.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision
The following files are available for download:
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
财报
2024-08-16
OSLO, Norway, Aug. 16, 2024 /PRNewswire/ --
In first half of 2024, Navamedic ASA (OSE: NAVA)
, a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 277.2 million, up 12.8 per cent from the corresponding period last year. Adjusted EBITA amounted to NOK 41.1 million compared to NOK 26.3 million in 2023. The milestone payment of NOK 22.7 million following the agreement with Orion Corporation to market and sell Flexilev® and OraFID® in Europe is included.
During the first six months of 2024, Navamedic has delivered on its strategy across the business. Following the launch of Eroxon® at the start of the year, the company renewed its contract with the Norwegian Hospital Procurement Trust, whereby Navamedic will continue to supply Norwegian hospitals with antibiotics until 2027. This agreement is expected to contribute more than 20 per cent revenue growth to the overall antibiotics' portfolio.
In June, Navamedic signed a license and supply agreement with Orion Corporation (Orion) to market and sell Flexilev® and OraFID® in Europe. This agreement represents a major milestone in Navamedic's commercialisation strategy for Flexilev®. Orion has paved the way for Parkinson's disease treatment in Europe, making it a strong commercial partner for Navamedic.
"Halfway into 2024, Navamedic can look back at an exciting first six months. There has been a lot of activity across the business, which has broadened Navamedic's geographical reach and product portfolio. Having been early to identify treatment areas with significant medical need and consumer demand, such as supplying antibiotics to hospitals and obesity, we have seen good growth across our key business areas: RX, Consumer and Hospital," said Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
Operating results (EBIT) for the first six months of 2024 amounted to NOK 33.8 million, compared to NOK 9.9 million in 2023. Operating costs ended at NOK 77.8 million, compared to NOK 74 million last year. Net financial items ended at negative NOK 9.7 million and profit before tax was NOK 24 million.
Key figures and category update for the second quarter of 2024
Revenues for the second quarter amounted to NOK 156.3 million, up 26.2 per cent from last year. Adjusted EBITDA amounted to NOK 32.7 million, up from NOK 10.5 million in the second quarter of 2023. Gross margin for the quarter was 46.1 per cent, compared to 40.4 per cent in 2023. During the quarter, the company experienced steady growth across its three segments: Prescription Drugs (RX), Hospital and Consumer Health.
As part of the
Prescription Drugs (RX) category, sales of Mysimba® have remained stable in an increasingly competitive market. Imdur® and Forlax® have seen double digit growth year-over-year.
Within the
Hospital category, the antibiotics portfolio has delivered solid growth. The medical nutrition portfolio continues to deliver steady growth, delivering treatments for patients with Inborn Errors of Metabolism, which is considered a lifelong genetic disorder.
In the
Consumer Health category, Eroxon® was launched in Sweden in May, making it the first and only non-prescription treatment for erectile dysfunction in the country. It has also been a strong quarter for several hero products, including Absolut Torr and GeloRevoice, which are up 38 per cent and 35 per cent year-over-year, respectively. ThermaCare and Modifast continue to deliver stable sales. Navamedic plans to explore opportunities to expand both Absolut Torr and MedMade outside the Nordics
Outlook
Navamedic continues to see strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company.
"We continue to build on a solid foundation and are exploring further opportunities for market expansion with our own products. A key driver for everyone at Navamedic is to be a proud contributor to public health, which includes identifying treatments and products that can enhance people's quality of life and ensuring that they are accessible, either through hospitals or pharmacies," Andreassen concluded.
Presentation
Navamedic will present the results for the second quarter and first half of 2024 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link:
Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: [email protected]
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: [email protected]
About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision
The following files are available for download:
引进/卖出财报
2024-02-15
OSLO, Norway, Feb. 15, 2024 /PRNewswire/ --
Navamedic ASA (OSE: NAVA)
, a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. For the first time all three product categories were above the NOK 100 million mark.
The company's gross margin was 38.9 per cent for the year, down from 42.8 per cent in the year before. Adjusted EBITDA (EBITDA less acquisition cost) amounted to NOK 51.6 million, compared with NOK 51.7 million in 2022.
Operating results (EBIT) amounted to NOK 23.6 million, compared to NOK 44.4 million in 2022. Operating costs were higher than in 2022, mostly due to continued investments in growth initiatives. Also included in the EBITDA is a negative contribution of 4.8 MNOK from the Sensidose business.
"We are looking back at an eventful and transformative year. With the Sensidose acquisition, we gained a promising position in the market for treatment of Parkinson's Disease, and we renewed and secured new marketing and distribution agreements for several other high selling products, including Eroxon®, a clinically proven treatment of erectile dysfunction. Eroxon® was launched in Norway this week and will soon also be available in Sweden," said Kathrine Gamborg Andreassen, CEO of Navamedic.
"Furthermore, in the fourth quarter 2023, we signed a term sheet with the Finnish pharmaceutical corporation Orion Pharma, which we are currently finalising into an agreement for a licensing and supply of Flexilev® and OraFID® in Europe, products that were acquired through Sensidose. In Sweden, Norway and Denmark, we will market and sell these products from our own proven platform," Andreassen added.
Revenues in the fourth quarter of 2023 was NOK 125 million, up 8.1 percent from the same period last year. Gross margin was 36.5 per cent, down from 42.9 per cent, and Adjusted EBITDA was NOK 7.9 million, compared with NOK 15.7 million in the fourth quarter of 2022.
Category update
In the
Consumer Health category, Modifast cemented its position with continued strong sales in Sweden, and Absolute Torr gained traction with a 54 per cent growth year-over-year in the fourth quarter. Further growth to be achieved through combination of consumer and pharmacy engagement, sale of unique and profitable products in home markets and out-licensing of own products elsewhere.
The
Hospital category saw double-digit growth year-over-year across the portfolio of antibiotics and medical nutrition products. It also renewed exclusive rights to Vitaflo's medical nutrition products across the Nordic for five more years. Winning new antibiotic tenders is core in the growth strategy, along with initiatives to expand and secure new marketing authorisations.
The
Prescription Drugs category had strong growth across various therapeutic areas, with continued high demand for Mysimba for obesity treatment, and strong sales of Imdur, Nitrolingual and Forlax. In this category, Navamedic is now preparing rollout of Flexilev with MyFID® and OraFID® in the Nordic countries and out-licensing in the rest of Europe.
Outlook
Navamedic sees continued strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company with a 15 per cent EBITDA margin.
"We are building on a solid foundation. We will continue to strengthen our existing business by leveraging our highly scalable market access platform. We will explore opportunities for market expansion with own products and increase company value by acquiring and strengthening own products and brands while increasing gross margins through careful management of our product portfolio," Andreassen concluded.
Navamedic will present the results for the fourth quarter and full year 2023 at 08.30 today. The presentation will take place at Dronning Eufemias Gate 16 in Oslo, and will be available to follow via webcast at the following link:
Representatives from Navamedic's management team, CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation.
EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section of the attached presentation on slide 23.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: [email protected]
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: [email protected]
About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
The following files are available for download:
并购引进/卖出
100 项与 聚乙二醇4000 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 便秘 | 日本 | 1979-04-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床4期 | 功能性便秘 维持 | 92 | PEG 4000 at a dose of 0.7 g/kg | 簾製憲製網鹽夢憲顧夢(鬱齋壓齋淵製獵選廠糧): relative risk = 0.9 (95% CI, 0.78 ~ 1.03) 更多 | 积极 | 2015-01-01 | |
PEG 4000 at a dose of 0.3 g/kg | |||||||
临床3期 | 88 | Lactulose | 鏇夢簾襯製膚獵鏇糧餘(餘壓製襯鏇選鹹淵鏇齋) = 顧衊築齋範鬱遞觸獵鏇 積構憲鹽繭築憲鹽窪壓 (窪遞淵鬱鬱餘鏇範顧鑰 ) | 积极 | 2014-06-19 | ||
鏇夢簾襯製膚獵鏇糧餘(餘壓製襯鏇選鹹淵鏇齋) = 糧範願淵憲齋鏇簾膚壓 積構憲鹽繭築憲鹽窪壓 (窪遞淵鬱鬱餘鏇範顧鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用